Full Press Release Details
Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies.
RAPP
Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies
Key Takeaway: Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+91%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
RAP-219
Phase 3 · Focal Seizure